Back

Watch Compare

INTEGRATED BIOPHARMA INC

Data quality: 83%

INBP

OTC Manufacturing Chemicals

$0.29

$0.00 (0.00%)

Mkt Cap: 9.01 M

Price

$0.29

Mkt Cap

9.01 M

Day Range

$0.29 — $0.29

52-Week Range

$0.25 — $0.42

Volume

500

Open $0.29

50D / 200D Avg

$0.31

5.17% below

50D / 200D Avg

$0.31

5.63% below

Quick Summary

Key Takeaways

Earnings grew 621.43% over the past year

Generating 2.82 M in free cash flow

ROIC of 1.41% — low return on invested capital

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)621.43%

FCF Growth (3Y)29.58%

Quality

Return on Equity

-1.02%

Above sector avg (-53.41%)

ROIC1.41%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio5.03

Interest Coverage288.50

Valuation

PE (TTM)

-43.72

Below sector avg (-1.48)

P/B Ratio0.46

EV/EBITDA4.20

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)

Metric	Stock	Sector Median
P/E	-43.7	-1.5
P/B	0.5	1.6
ROE %	-1.0	-53.4
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.8
D/E	—	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	621.43%	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	-43.65%
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-206,000.0
ROE	-1.02%	ROA	-0.84%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	2.82 M
ROIC	1.41%	FCF Growth (3Y)	29.58%
Safety
Debt / Equity	N/A	Current Ratio	5.03
Interest Coverage	288.50	Asset Turnover	N/A
Working Capital	14.28 M	Tangible Book Value	19.77 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-43.72	Forward P/E	N/A
P/B Ratio	0.46	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	4.20	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	31.33%
Market Cap	9.01 M	Enterprise Value	3.69 M
Per Share
EPS (Diluted TTM)	0.00	Revenue / Share	N/A
FCF / Share	0.09	OCF / Share	0.10
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	-41.14%
EPS CAGR (10Y)	-5.52%
Efficiency
CapEx / Revenue	N/A	FCF Conversion	-1369.90%
SBC-Adj. FCF	2.63 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	—	—	—	—
Net Income	808,000.0	112,000.0	-34,000.0	3.84 M	8.01 M
EPS (Diluted)	0.03	0.00	0.00	0.12	0.25
Gross Profit	5.56 M	3.88 M	4.06 M	6.55 M	9.48 M
Operating Income	2.02 M	251,000.0	120,000.0	2.75 M	5.78 M
EBITDA	—	—	—	—	—
R&D Expenses	—	—	—	—	—
SG&A Expenses	3.54 M	3.63 M	3.94 M	3.81 M	3.70 M
D&A	318,000.0	319,000.0	351,000.0	336,000.0	337,000.0
Interest Expense	46,000.0	52,000.0	52,000.0	128,000.0	256,000.0
Income Tax	1.25 M	156,000.0	134,000.0	-1.24 M	-766,000.0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	24.90 M	26.21 M	25.43 M	25.25 M	25.44 M
Total Liabilities	4.58 M	6.97 M	6.57 M	6.68 M	11.11 M
Shareholders' Equity	20.32 M	19.24 M	18.86 M	18.58 M	14.33 M
Total Debt	—	—	0.0	186,000.0	3.64 M
Cash & Equivalents	3.62 M	1.68 M	1.32 M	331,000.0	210,000.0
Current Assets	18.76 M	17.88 M	16.37 M	16.63 M	18.00 M
Current Liabilities	4.25 M	6.12 M	4.83 M	5.26 M	9.24 M